Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 3
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic cast…
Prostate Cancer Metastatic
Merck Sharp & Dohme LLCNCT06136624
Phase 1
Phase 1/2 Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed …
Prostate Cancer Metastatic DiseaseProstate Cancer (Adenocarcinoma)
Halda Therapeutics OpCo, Inc.NCT06800313
Observational
Contribution of Race to Nutritional Approach to Lower Cardiovascular Risk Factors in Men Undergoing Androgen Deprivation Therapy
There is a well-documented association between androgen deprivation therapy (ADT) and cardiovascular morbidity. A majority of men on ADT gain weight contributi…
Prostate Cancer Metastatic Disease
University of California, Los AngelesNCT06682390
Observational
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy: POWER Trial
The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves car…
Androgen Deprivation TherapyProstate CancerProstate Cancer Metastatic
Dana-Farber Cancer InstituteNCT05327465